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Abstract-Sheldon [l] demonstrated the usefulness of mathematical models in cancer esearch for 
gaining clinical insight. In particular, he showed that greater difficulties have to be surmounted when 
modelling chemotherapy treatment of cancer tumours as compared with radiotherapy treatment. 
The present analysis concentrates specifically on developing appropriate mathematical models for 
investigating the effect of toxic drugs on tumour growth and is a direct development of the work 
described by Wheldon [l]. The qualitative results obtained provide us with greater insights into 
effective chemotherapy treatment. 
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1. INTRODUCTION 
The development of appropriate mathematical models for investigating the treatment of cancer 
by chemotherapy is far more difficult than for investigating radiotherapy. This is due to the 
complexity of action of anticancer drugs either singly or in combination. 
Following Wheldon [l], we will focus attention on some special areas of cancer chemotherapy 
where mathematical models seek to derive results, which are qualitative in nature and which 
will be of clinical interest. In particular, a more generalised form of tumour kinetics than that 
employed by Wheldon [l] will be utilised with regard to tumour response to chemotherapy. 
2. DRUG ACTION ON TUMOUR GROWTH 
For present modelling purposes, the drugs used in chemotherapy will be classified in terms 
of their cell cycle specificity [2]. For simplicity, these drugs will be classified into two groups, 
viz., cycle-nonspecific and cycle-specific. Drugs will be classified as cycle-nonspecific if, to a first 
approximation, they are toxic to cells at any position in their cell cycle. (For a concise overview of 
cell population kinetics, see [3]; for a comprehensive mathematical treatment, see [2].) However, 
those drugs that are toxic only to cells in their dividing phase will be classified cycle-specific. 
It is important to realise that, in practice, drugs belong to a broad spectrum in terms of cell 
specificity (for quantitative data, see [4]). 
Rapidly growing tumours are often the most responsive to chemotherapy; this is likely to be 
due to the cycle-specific mode of action of many chemotherapeutic drugs. This inference comes 
as a result of our knowledge of tumour growth. We will now attempt to develop some models to 
describe the effect of toxic drugs on tumour growth in order to illicit further inferences of clinical 
interest. 
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3. “GENERALIZED-EX” GROWTH KINETICS 
We will first look at a mathematical model for tumour growth which was employed previously 
as a basis for investigating radiotherapy treatment of tumours (see [5]). This model will then be 
modified in line with further work described by Wheldon [l] in order to investigate chemotherapy 
treatment of tumours. 
Let N(T) denote the number of cancerous cells at time t, which are proliferating at a rate 
governed by the differential equation 
where the parameters (Y (2 0), A, 0(> 0) are determined from the growth characteristics of the 
tumour under investigation. The solution of the differential equation (1) may be expressed in the 
form 
N(t)=No{[~]Y+e-*~(l-[~]n)}-l’~, (2) 
where Ne = N(t = 0). 
Limiting forms of (1) of particular interest for tumour growth kinetics are: 
(i) the Gompertzian growth rate, 
a-+0: 
dN 
dt= 
(ii) the Verhulst growth rate, 
(iii) the Exponential growth rate, 
We shall refer to (1) as the “Generalised-growth” equation (see [5].) 
There is experimental evidence [l] that many tumours grow exponentially during the initial 
‘latent’ period before they become observable and subsequently follow Gompertz-type kinetics, or 
perhaps other kinetics associated with (1). This resulted in Wheldon [l] introducing the following 
‘Gomp-Ex’ growth model to cope with the two phase growth. 
N I N,, 
--= 
NINc, 
(6a,b) 
where A, p are tumour growth parameters, and N, corresponds to the tumour cell number at 
which transition between the two phases of growth occurs. Of course, in practice, there is not 
likely to be a sharp transition. 
It seems entirely reasonable to generalize this model to the following “Generalised-Ex” model. 
Consider the system: 
N < N,, 
--= 
[I- ($>“I, NZN,, 
U’a,b) 
where A, Xi, and cr are tumour growth parameters. Then, there will be the limiting forms of 
particular clinical interest corresponding to the results (3)-( 5). 
This “Generalised-Ex” model will now be employed as a basis for investigating cycle-non- 
specific chemotherapy treatment of tumours. It is a natural development of the work described 
by Wheldon [l]. 
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4. CYCLE-NONSPECIFIC CHEMOTHERAPY: 
“GENERALIZED-EX” GROWTH KINETICS 
Consider the effect of exposing a tumour cell population to a cycle-nonspecific drug at concen- 
tration C(t). Then the drug will be equally toxic to proliferating or nonproliferating cells. Now 
a cell kill term must be added to system (7a,b) to represent the effect of the drug on tumour 
growth. Assuming an exponential dose-response relationship, with parameter p, between drug 
concentration and rate of cell killing the required modified form of (7a,b) will be: 
1 dN x -PC(% N I N,, --= 
N dt A+% [l - ($)“] -PC(t), N 2 Nc. 
@,b) 
The solution of this system will, of course, depend on the functional form of C(t) and, in general, 
resort would be made to numerical methods for obtaining results, provided numerical estimates 
of the parameters were available. However, for the case of constant concentration Co, an analytic 
solution of the system can be found but its form is dependent on certain parameter constraints 
and also on whether the size of the cell population when the treatment is initiated (i.e., No) is 
greater or less than N,. The various cases are detailed below. The first four cases refer to the 
situation when NO 2 N, and the last three refer to the situation when NO 5 N,. 
CASE 1. No>Nc; A-pCo>O. 
1 
llff 
No A BNg+(A-BN$)exp(-aAt) ’ a > 0, N(t) = (90) 
NO exp 
K 
* +ln (a)) (1 - exp(-X1 t)I] , Q = 0, 
A=X-pCo+2, B=--& a > 0. 
c 
(94 
where 
CASE 2. No 2 N,; -2 < X - pCo < 0. 
1 
l/a 
No 
A 
BNg+(A-BN;)exp(-aAt) ’ a # 0, t I t1, 
N(t) = 
NO exp 
K 
* +ln (2)) (1 - exp(-X1 Q)] , a = 0, t I h, 
W,b) 
NC exp [(A - /I CO) (t - b>l , tltl, 
where 
t1 = 
z9n[(a)“+&((%)“-l)]~ cr’o, 
*In 1+ A_;co In j$ , 
[ ( >I cu =0, 
and where A and B are given by (SC). 
CASE 3. No 2 N,; X-PC, = -%, CI > 0. 
[ I 
l/a 
N(t) = 
-$+No” , i! I t2, 
NC exp [-$(t - t2)] , t L t2, 
where 
t2 = F [N,” - N,*] . 
CASE4. No2Nc; X-/JC~<- + cr>o. 
W-W 
(lhb) 
WC) 
76 J. R. USHER 
where 
, 
NC exp [(A - c1 Co) (t - t3)l , 
t3=-&In B - GW,a) 1 B - (A/N;) ’ 
and where A and B are given by (SC). 
CASES. &<N,; i!-/ico>o. 
N(t) = ( 
where 
NO exp [(A - p CO> 4, 
NC exp [ (9) [l - exp (-xl (t - t4))1] y 
t4= (h_;Co)ln 2 ( ) 
and where A and B are given by (SC). 
CASE 6. No L: NC; A--pCo=O. 
N(t) = No, w 2 0. 
CASEi,. NoIN,; x-pco<O. 
t I t3, 
t 2 t3r 
W&b) 
(124 
t I t4, 
a > 0, t>t4, (13ahc) 
a = 0, t 2 t4, 
(134 
N(t) = NO exp [(A - GO) tl , \dt 2 0. (15) 
The asymptotic values for N(t) as t + cm in the above cases provide useful information in regard 
to the likely success or otherwise of the corresponding treatment. They are given below. 
CASE 1. 
(i) (Y > 0: 
lim N(t) = 
No, ifX-pCe= % [(a)” - 11’ 
t-co 
NC, ifX-pCc=O. 
Also,ifX-pCo> %[($Q)“--I] orifO<X-pCo<%[($Q)a-I],then 
lim N(t) = NC 
a(X-pCo)+X1 1’a 
t-too Xl I . 
However, if X - p Co > 2 [($Q), -I], then 
N a(X-pCo)+~l c 
x1 1 
l/a >No 
, 
whereasifO<A-pCo< 2 [(a)” -11, then 
(l%b) 
(17) 
N <N 
c e 
a(A-PCo)+Xl l’a<N 
Xl 1 0. 
(See Figure 1.) 
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Figure 1. Graphs of tumour cell population size: NO 2 N,, a > 0. (See equations 
(lOd), (llc), and (12~)). 
(ii) a = 0: 
;iix N(t) = 
No, ifX--jdCo=XlIn $Q , 
( > c 
Nc, ifX-pCo=O. 
AlsoifX-pCo>Xlln @ orifO<X-pCg<X1ln 2 ,then 
( > ( > 
Wa,b) 
lim N(t) = N,exp A-PC0 
t-+aJ [ I. Xl 
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whereas if 0 < X - 
NC c NC exp X-PC0 
[ 1 Xl < No. 
(See Figure 2.) 
N(t) 
UNTREATED / 
GROWTH / A -pc Pcexp o 
I 1 1  
N 
>hllll N 0 0 0 c 
1’ / x -PC~= A,ln 1 -1 5 N 
~CocXlln 2 ,then 
( > 
X-MC 
N exp 0 
c 
[ 1 4 
1 l t 
tl (see equation (lOeli 
Figure 2. Graphs of tumour cell population size: No 2 NC, CL = 0. (See equa- 
tion (lOe).) The graphs are limiting forms of graphs in Figure 1, ss cx + 0. 
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N(t) 
t4 (see equation (13d)) 
Figure 3. Graphs of tumour cell population size: NO 5 N,. (See equation (13d).) 
CASES 2, 3, 4. 
lim N(t) = 0. 
t-Ku 
CASE 5. 
Q (X-p co)+xl l/a NC x1 1 3 )iir N(t) = cr > 0, 
N,exp y , [ 1 a = 0. 
(19) 
POa,b) 
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lim N(t) = No. 
t+cc (21) 
CASE 7. 
lim N(t) = 0. 
t-e0 (22) 
The qualitative behaviour of the solutions representing the tumour cell population size in the 
above cases, including their asymptotic behaviour as t + 00 are illustrated in Figures 1, 2, and 3. 
The graph representing untreated tumour growth (with Co = 0) is shown in each of the figures. It 
can clearly be seen that the value of X - ~1 CO is the significant factor in distinguishing the different 
modes of behaviour. We can see that in Cases 2, 3, 4, and 7, significant tumour regression occurs 
(we must bear in mind that for practical purposes treatment time is finite!). While in Case 1.i 
with X-PC0 = * [(~)a-1],inCssel.iiwith~-~Co=~lln(~),andinCase6,thereis 
an exact balance between “tumour growth” and “cell kill.” However, in Cases l.i, l.ii (excluding 
the sub-cases where “tumour growth” balances “cell kill” just referred to) and in Case 5 only 
very limited “success” will be achieved. 
There is another important implication of the above analysis which should be noted. For the 
situation when No > N,, the critical drug concentration level Ct) which produces a balance 
between “tumour growth” and “cell kill” is given by 
@ = 
{ 
;[x-+[($$-111, if (Y > 0, 
i 
[ 
X - Xrln 2 
( >I E ’ 
ifa=O. 
(230) 
Thus, the drug concentration level required to initiate tumour regression must satisfy the in- 
equality 
co > &). (24) 
From (23a,b) and (24), we see that the required concentration level for initiating tumour 
regression will be dependent on the cell population size when the drug is first applied, and will 
be larger, the smaller the population. This is the phenomenon of kinetic resistance which has 
already been shown to exist for Gompertzian growth [l]. However, if NO 5 N,, the critical drug 
concentration level corresponding to (23a,b) is given by 
In this situation, kinetic resistence will not occur. 
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